AstraZeneca to buy US-based CinCor in $1.8bn deal
9th Jan 2023 07:17
(Sharecast News) - AstraZeneca said on Monday that it has agreed to buy US-based clinical-stage biopharmaceutical company CinCor in a $1.8bn deal.
Read moreAstraZeneca gets new approvals in Japan on three drugs
28th Dec 2022 07:56
(Sharecast News) - AstraZeneca announced on Wednesday that its immunotherapies 'Imfinzi', or durvalumab, and 'Imjudo', or tremelimumab, have been approved in Japan for the treatment of three cancer types - advanced liver, biliary tract and lung.
Read moreAstraZeneca's Imfinzi plus Imjudo recommended for EU approval
19th Dec 2022 08:07
(Sharecast News) - AstraZeneca said on Monday that its Imfinzi (durvalumab) and Imjudo (tremelimumab) combinations have been recommended for marketing authorisation in the European Union for advanced liver and lung cancers.
Read moreAstraZeneca's Forziga recommended for EU use
19th Dec 2022 07:04
(Sharecast News) - AstraZeneca's Forxiga drug has been recommended for approval in the EU for symptomatic chronic heart failure, the pharma company said on Monday.
Read moreFDA gives AstraZeneca extension on cancer drug application
15th Dec 2022 07:49
(Sharecast News) - The US Food and Drug Administration has given AstraZeneca and MSD a three month extension to review a new drug application for its prostate cancer treatment Lynparza.
Read moreAstraZeneca hails positive findings in breast cancer drug trial
8th Dec 2022 14:58
(Sharecast News) - AstraZeneca said on Thursday that a phase III trial of its capivasertib drug in combination with Faslodex (fulvestrant) had demonstrated a "statistically significant and clinically meaningful" improvement in progression-free survival in patients with hormone receptor (HR)-positive, HER2-low or negative, locally advanced or metastatic breast cancer.
Read moreAstraZeneca sells US manufacturing site
30th Nov 2022 07:46
(Sharecast News) - AstraZeneca has agreed to sell a US manufacturing site to National Resilience.
Read moreAstraZeneca to buy biotech Neogene for up to $320m
29th Nov 2022 07:12
(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy biotechnology group Neogene for up to $320m, as it looks to accelerate its ambition in oncology cell therapy.
Read moreThree AstraZeneca drugs recommended for EU approval
14th Nov 2022 07:22
(Sharecast News) - AstraZeneca announced on Monday morning that three of its drugs had been recommended for approval in the European Union.
Read moreAstraZeneca's Imfinzi gets FDA approval for lung cancer treatment
11th Nov 2022 07:27
(Sharecast News) - AstraZeneca on Friday said its Imfinzi drug in combination with the Imjudo antibody and platinum-based chemotherapy has been approved in the US for the treatment of adult patients with stage IV non-small cell lung cancer.
Read moreAstraZeneca lifts full-year earnings guidance after strong Q3
10th Nov 2022 08:27
(Sharecast News) - AstraZeneca lifted its full-year earnings guidance on Thursday following a solid third quarter.
Read moreFDA committee votes in favour of AstraZeneca asthma candidate
9th Nov 2022 08:25
(Sharecast News) - AstraZeneca announced on Wednesday that a US Food and Drug Administration (FDA) committee has voted in favour of an adult asthma treatment.
Read moreAstrazeneca's Beyfortus receives EU approval
4th Nov 2022 07:02
(Sharecast News) - Drugmaker AstraZeneca said on Friday that its Beyfortus asset had received European Union approval for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants.
Read moreAstraZeneca breast cancer drug shows 'significant' improvement in trial
26th Oct 2022 07:56
(Sharecast News) - AstraZeneca said its capivasertib breast cancer drug combined with Faslodex hormone treatment demonstrated a "statistically significant and clinically meaningful improvement" in progression-free patient (PFS) survival during a late-stage trial.
Read moreAstraZeneca says Fasenra fails to meet one trial endpoint
25th Oct 2022 07:51
(Sharecast News) - AstraZeneca said its Fasenra treatment for a rare inflammatory disease of the oesophagus failed to meet one of the two dual-primary endpoints in a phase 3 trial.
Read more